Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Efficacy, and Immunogenicity of Daily Subcutaneous Administration of 5 ?g/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
Status: Enrolling
Updated:  12/31/1969
1960
mi
from 91732
Columbus, OH
A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Efficacy, and Immunogenicity of Daily Subcutaneous Administration of 5 ?g/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site
1960
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Efficacy, and Immunogenicity of Daily Subcutaneous Administration of 5 ?g/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
Status: Enrolling
Updated:  12/31/1969
mi
from 91732
Sofia,
A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Efficacy, and Immunogenicity of Daily Subcutaneous Administration of 5 ?g/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
Status: Enrolling
Updated: 12/31/1969
Teva Investigational Site 59104
mi
from 91732
Sofia,
Click here to add this to my saved trials
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated:  12/31/1969
72
mi
from 91732
California City, CA
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated: 12/31/1969
72
mi
from 91732
California City, CA
Click here to add this to my saved trials
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated:  12/31/1969
28
mi
from 91732
Corona, CA
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
28
mi
from 91732
Corona, CA
Click here to add this to my saved trials
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated:  12/31/1969
25
mi
from 91732
Fountain Valley, CA
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
25
mi
from 91732
Fountain Valley, CA
Click here to add this to my saved trials
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated:  12/31/1969
13
mi
from 91732
Los Angeles, CA
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated:  12/31/1969
2315
mi
from 91732
Hialeah, FL
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2315
mi
from 91732
Hialeah, FL
Click here to add this to my saved trials
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated:  12/31/1969
2130
mi
from 91732
Orange Park, FL
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2130
mi
from 91732
Orange Park, FL
Click here to add this to my saved trials
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated:  12/31/1969
1729
mi
from 91732
Chicago, IL
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated:  12/31/1969
1400
mi
from 91732
Springfield, MO
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1400
mi
from 91732
Springfield, MO
Click here to add this to my saved trials
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated:  12/31/1969
2032
mi
from 91732
Cleveland, OH
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2032
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated:  12/31/1969
2262
mi
from 91732
Fredericksburg, VA
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2262
mi
from 91732
Fredericksburg, VA
Click here to add this to my saved trials
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated:  12/31/1969
6113
mi
from 91732
Buenos Aires,
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
Status: Enrolling
Updated: 12/31/1969
6113
mi
from 91732
Buenos Aires,
Click here to add this to my saved trials
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
572
mi
from 91732
Salt Lake City, UT
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
University of Utah
572
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
345
mi
from 91732
Phoenix, AZ
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
Phoenix Children's Hospital
345
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
817
mi
from 91732
Denver, CO
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
University of Colorado
817
mi
from 91732
Denver, CO
Click here to add this to my saved trials
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
2103
mi
from 91732
Gainesville, FL
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
University of Florida College of Medicine
2103
mi
from 91732
Gainesville, FL
Click here to add this to my saved trials
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
1729
mi
from 91732
Chicago, IL
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
Ann & Robert H. Lurie Children's Hospital of Chicago
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
1812
mi
from 91732
Louisville, KY
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
University of Louisville
1812
mi
from 91732
Louisville, KY
Click here to add this to my saved trials
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
2449
mi
from 91732
New Hyde Park, NY
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
Cornell University
2449
mi
from 91732
New Hyde Park, NY
Click here to add this to my saved trials
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
2351
mi
from 91732
New York, NY
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
New York Presbyterian Hospital-Weill
2351
mi
from 91732
New York, NY
Click here to add this to my saved trials
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
1880
mi
from 91732
Cincinnati, OH
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
1961
mi
from 91732
Columbus, OH
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
Nationwide Children's Hospital
1961
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
1171
mi
from 91732
Oklahoma City, OK
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
University of Oklahoma Health Sciences Center
1171
mi
from 91732
Oklahoma City, OK
Click here to add this to my saved trials
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
2269
mi
from 91732
Richmond, VA
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University
2269
mi
from 91732
Richmond, VA
Click here to add this to my saved trials
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
6666
mi
from 91732
Plovdiv,
BAX 855 Pediatric Study
A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
UMHAP Sveti Georgi EAD
6666
mi
from 91732
Plovdiv,
Click here to add this to my saved trials
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated:  12/31/1969
358
mi
from 91732
Scottsdale, AZ
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
358
mi
from 91732
Scottsdale, AZ
Click here to add this to my saved trials
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated:  12/31/1969
95
mi
from 91732
La Jolla, CA
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated: 12/31/1969
University of California San Diego UCSD Moores Cancer Center
95
mi
from 91732
La Jolla, CA
Click here to add this to my saved trials
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated:  12/31/1969
103
mi
from 91732
San Diego, CA
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated: 12/31/1969
UC San Diego Medical Center - Hillcrest
103
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated:  12/31/1969
2434
mi
from 91732
New York, NY
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Medical College/New York Presbyterian Hospital
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated:  12/31/1969
1729
mi
from 91732
Milwaukee, WI
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated: 12/31/1969
Froedtert Hospital, Medical College of Wisconsin
1729
mi
from 91732
Milwaukee, WI
Click here to add this to my saved trials
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated:  12/31/1969
2435
mi
from 91732
New York, NY
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated: 12/31/1969
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated:  12/31/1969
2033
mi
from 91732
Cleveland, OH
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated: 12/31/1969
The Cleveland Clinic, Taussig Cancer Institute
2033
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated:  12/31/1969
573
mi
from 91732
Salt Lake City, UT
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute at University of Utah
573
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated:  12/31/1969
mi
from 91732
Kobe,
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated: 12/31/1969
Kobe University Hospital
mi
from 91732
Kobe,
Click here to add this to my saved trials
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated:  12/31/1969
1932
mi
from 91732
Ann Arbor, MI
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated: 12/31/1969
University of Michigan
1932
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated:  12/31/1969
572
mi
from 91732
Salt Lake City, UT
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated: 12/31/1969
University of Utah (Huntsman Cancer Hospital)
572
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated:  12/31/1969
348
mi
from 91732
Phoenix, AZ
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Building, Phoenix
348
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated:  12/31/1969
343
mi
from 91732
Phoenix, AZ
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Hospital
343
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated:  12/31/1969
95
mi
from 91732
La Jolla, CA
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated: 12/31/1969
UC San Diego Moores Cancer Center - Investigational Drug Services
95
mi
from 91732
La Jolla, CA
Click here to add this to my saved trials
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated:  12/31/1969
94
mi
from 91732
La Jolla, CA
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status: Enrolling
Updated: 12/31/1969
UCSD Medical Center Clinical Laboratory - La Jolla
94
mi
from 91732
La Jolla, CA
Click here to add this to my saved trials
Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases
Status: Enrolling
Updated:  12/31/1969
961
mi
from 91732
Seattle, WA
Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer ResearchCenter
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
Status: Enrolling
Updated:  12/31/1969
2277
mi
from 91732
Bethesda, MD
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome
A Phase III Double-Blind Randomized Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients With WHIM Syndrome.
Status: Enrolling
Updated:  12/31/1969
2277
mi
from 91732
Bethesda, MD
Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome
A Phase III Double-Blind Randomized Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients With WHIM Syndrome.
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)
Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)
Status: Enrolling
Updated:  12/31/1969
2373
mi
from 91732
Philadelphia, PA
Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)
Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)
Status: Enrolling
Updated: 12/31/1969
Abramson Cancer Center of the University of Pennsylvania
2373
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B
An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B
Status: Enrolling
Updated:  12/31/1969
343
mi
from 91732
Phoenix, AZ
Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B
An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
343
mi
from 91732
Phoenix, AZ
Click here to add this to my saved trials
Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B
An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B
Status: Enrolling
Updated:  12/31/1969
364
mi
from 91732
Sacramento, CA
Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B
An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
364
mi
from 91732
Sacramento, CA
Click here to add this to my saved trials
Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B
An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B
Status: Enrolling
Updated:  12/31/1969
1919
mi
from 91732
Atlanta, GA
Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B
An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1919
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B
An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B
Status: Enrolling
Updated:  12/31/1969
1729
mi
from 91732
Chicago, IL
Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B
An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1729
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B
An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B
Status: Enrolling
Updated:  12/31/1969
1793
mi
from 91732
Indianapolis, IN
Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B
An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1793
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials